Diplomat receives limited-distribution contract for BETHKIS® (tobramycin inhalation solution)
FLINT, Mich. — Nov. 22 2013 — Diplomat, the nation’s largest independent specialty pharmacy, has been chosen as a distributor for BETHKIS® (tobramycin inhalation solution.) BETHKIS® is a concentrated dosing solution for the treatment of chronic bacterial lung infections caused by P. aeruginosa in cystic fibrosis patients. BETHKIS® was approved by the FDA in October 2013 with a product launch this fall by Cornerstone Therapeutics. Diplomat has access to dispense BETHKIS® immediately.
According to the Cystic Fibrosis Foundation, more than 30,000 children and adults are living with cystic fibrosis, an inherited chronic disease, with 1,000 new cases diagnosed each year. Cystic fibrosis is caused by a defect in the cystic fibrosis transmembrane conductance regulator gene. This defect causes the body to produce unusually thick, sticky mucus that alters normal processes in the lungs and leads to chronic bronchial infections. Inhaled tobramycin is recommended to improve lung function and reduce exacerbations for cystic fibrosis patients aged 6 or older experiencing moderate to severe lung disease and showing P. aeruginosa in cultures of the airways.
Per manufacturer’s instructions, BETHKIS® is administered as a concentrated solution delivering 300mg of nebulized tobramycin in only 4mL, twice daily in alternating 28-day cycles. BETHKIS® is not recommended for patients with a known hypersensitivity to any aminoglycoside.
BETHKIS® is marketed by Cornerstone Therapeutics Inc. based in Cary, N.C. Full prescribing information for BETHKIS® is available on the Cornerstone Therapeutics website.
About Cornerstone Therapeutics, Inc.
Founded in 2000, Cornerstone Therapeutics is a specialty pharmaceutical company focused on commercializing products for the hospital, niche respiratory and related markets.
Contact: Barbara Fornasiero, EAFocus Communications; 248.651.7536, Cell: 586.817.8414, firstname.lastname@example.org. Abigail Bearman, Diplomat; 810.768.9563; email@example.com. Gary Rice, R.Ph., Diplomat; 810.768.9863, firstname.lastname@example.org.
@PharmacDailyRT @PharmacDaily: @DiplomatRx to distribute Puma Biotechnology’s new cancer drug $DPLO https://t.co/gl0v6WURVV4 days ago
@DiplomatRxNerlynx (neratinib) tablets for HER2+ Breast Cancer in the Extended Adjuvant Setting https://t.co/vi3ACWhbfe5 days ago
@AJPB_JournalRT @AJPB_Journal: Be sure to check out our Insights page featuring videos of Cheryl Allen from @DiplomatRx discussing #RA https://t.co/qxZc…2 weeks ago
@DiplomatRxWe're with @340BCoalition this week in Washington D.C.! Come say hello.2 weeks ago
@SpecialtyPTimesRT @SpecialtyPTimes: Rheumatoid Arthritis Treatment Guidelines https://t.co/sEhe74UozC #rheumatoidarthritis @DiplomatRx3 weeks ago